Naira P. Martnez Vera1, Klaus Langer2, Lavor Zlatev2, Robert Wronsky3, Manfred Windisch3, Hagen von Briesen4, Sylvia Wagner5, Motti Deutsch6, Claus Pietrzik7
1Department of Neurology, Medical University of Graz, Graz, Styria, Austria; 2Institut fr Pharmazeutische Technologie und Biopharmazie,WWU Mnster, Germany; 3JSW Life Sciences GmbH, Grambach, Austria; 4Department of Cell Biology & Applied Virology, Fraunhofer-Institute for Biomedical Engineering, St. Ingbert, Germany; 5Department of Cell Biology & Applied Virology, Fraunhofer-Institute for Biomedical Engineering, St. Ingbert, Germany; 6Physics Department, Schottenstein Center for the Research and Technology of the Cellome, Bar llan University, Israel; 7Institute of Pathobiochemistry, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
Nanoparticles (NP) are expected to allow a more effective application of therapy by facilitating transport of drugs over the blood brain barrier (BBB). This experimental study focused on the development and in vivo testing of magnetite labeled NP. Following the optimization of the R1 relaxivity of different NP formulas in phantoms, the NP were administered intravenously in rats. The distribution and uptake then was assessed by T1 mapping and T1 weighted sequences. Most pronounced NP accumulations were observed in the liver and spleen. Using a histogram analysis, also a small but significant uptake was observed in the brain